Stock D4S DAIICHI SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Daiichi Sankyo Co., Ltd. Deutsche Boerse AG

Equities

D4S

JP3475350009

Real-time Estimate Tradegate
Other stock markets
 15:29:15 2024-05-15 EDT 		5-day change 1st Jan Change
32.49 EUR -0.52% Intraday chart for Daiichi Sankyo Co., Ltd. +1.92% +30.91%
04:04pm Merck to present new oncology data CF
08:06am IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Merck to present new oncology data
CF
IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court
MT
Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost
RE
Remsons, Daiichi Infotainments Form Joint Venture
MT
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement
MT
AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow
CI
AstraZeneca makes progress with Truqap and Enhertu cancer treatments
AN
AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study
MT
Hipgnosis Songs Fund backs new Blackstone bid
AN
Scholz pledges further support for the pharmaceutical industry
DP
Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024
MT
AstraZeneca upbeat as cancer drugs underpin sales growth
AN
Daiichi Sankyo Company, Limited Announces Dividend for the Year Ended March 31, 2024, Payable on June 18, 2024 and Provides Dividend Guidance for Second Quarter of Fiscal Ending March 31, 2025
CI
Daiichi Sankyo Company, Limited Provides Dividend Guidance for Full Fiscal Ending March 31, 2025
CI
Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025
CI
Daiichi Sankyo Company, Limited announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.
CI
Daiichi Sankyo Company, Limited authorizes a Buyback Plan.
CI
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark
MT
AstraZeneca hails neurological data for Ultomiris, Soliris
AN
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. D4S Stock
  5. News Daiichi Sankyo Co., Ltd.
  6. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW